Epithelial ovarian cancer
Conditions
Brief summary
Level of CA-125 measured before cycles one-four of chemotherapy and preoperatively before DPDS.
Detailed description
Levels of hemoglobin, platelets, leucocytes, CRP, albumin, IL-6 and VEGF before every cycle of chemotherapy, preoperatively before DPDS and three weeks after the last cycle of chemotherapy., CA-125 measured before cycles five-seven of chemotherapy and three weeks after the last cycle of chemotherapy, The compliance to tinzaparin injections and occurrence of adverse events related to tinzaparin will be evaluated., Objectively confirmed VTE, i.e. pulmonary embolism, lower-limb deep vein thrombosis or upper extremity deep vein thrombosis. Death due to VTE.
Interventions
DRUGTINZAPARIN
Sponsors
Region Oestergoetland
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of CA-125 measured before cycles one-four of chemotherapy and preoperatively before DPDS. | — |
Secondary
| Measure | Time frame |
|---|---|
| Levels of hemoglobin, platelets, leucocytes, CRP, albumin, IL-6 and VEGF before every cycle of chemotherapy, preoperatively before DPDS and three weeks after the last cycle of chemotherapy., CA-125 measured before cycles five-seven of chemotherapy and three weeks after the last cycle of chemotherapy, The compliance to tinzaparin injections and occurrence of adverse events related to tinzaparin will be evaluated., Objectively confirmed VTE, i.e. pulmonary embolism, lower-limb deep vein thrombosis or upper extremity deep vein thrombosis. Death due to VTE. | — |
Countries
Sweden
Outcome results
None listed